PCN89 Cost Effectiveness of Treatment With New 6-Month Leuprorelin Acetate Formulation in Patients With Advanced Prostate Cancer

Abstract

native. Only direct medical costs were considered. Costs and outcomes were discounted at 5% yearly. The outcomes considered were life years (LY) and quality adjusted life years (QALY). RESULTS: The incremental cost-effectiveness analysis demonstrated that AA is the most economically attractive medication. When the incremental cost-effectiveness ratio (ICER) for LY and QALY gained was evaluated, AA was dominant with regards to C, being more effective (LY: 1.3559 vs 1.2895; QALY: 0.7977 vs 0.7329) with lower costs (R$79,974 vs R$90,025). CONCLUSIONS: AA is the best therapeutic option, with the best cost-effectiveness ratio, versus C for the treatment of patients diagnosed with advanced mCRPC under Brazilian private perspective.

Pharmacoeconomic analysis of leuprolide acetate (Eligard) 45 mg once in 6 months for advanced prostate cancer in Russian Federation

“…Единственное фармакоэкономическое исследова-ние, в ходе которого сравнивали разные аналоги ГнРГ, было выполнено с позиции службы здравоохранения Италии [18]. Оценивали затратную эффективность 3-месячных форм лейпрорелина 11,25 и 22,5 мг, трип-торелина 11,25 мг, бусерелина 9,9 мг и гозерелина 10,8 мг.…”